Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 

Letter From The Editor

Letter from the Editor, #744

This week I got to see exactly how easy it is for our patients to add extra calories and sugar to their daily routine. It seems that Labor Day is no longer a holiday worthy of a special section in the grocery store for holiday food. On August 14,...


Editor's Note, DCMS #203:

This week in Part 4 of our Homerun Slides series, Dr. Schwartz finishes up by looking at the treatments for LADA, MODY, type 1 and type 2 diabetes, and


Letter from the Editor #743

I am sure many of you have received an email or Facebook post to participate in the ALS Ice Bucket Challenge. I am amazed by the number of people who will actually have a bucket of ice poured over their heads, yet will not take the time to check...



Editor's Note, DCMS #202

MODY, cystic fibrosis, and Wolfram syndrome all have something in common. Believe it or not, they are all a form of diabetes. This week, our Clinical Text from the Handbook of Diabetes looks at


Editor's Note, SGLT-2 Inhibitors, Special Edition, August 2014

Recently JARDIANCE (Empagliflozin) was approved for use, making it the third in this new class of medications. The first two, Invokana (canagiflozin) and Farxiga (dapagliflozin), have had relatively good acceptance into the marketplace especially...


Editor's Note, GLP-1 Agonist August 2014 Special Edition

It is always interesting when two legends in diabetes care sit down and have a conversation about the use of medications in patient care. Usually these thought leaders are early adopters when it comes to using medication combinations for diabetes....


Letter from the Editor, #742

  Sanofi is expanding its insulin portfolio to include the new inhaled insulin, Affreza. While it may not perform in the market at the scale of Lantus, I, for one, am glad that Sanofi is doing this. Five years ago a...


Editor's Note, DCMS #201

Sometimes when we prepare this newsletter, the articles, slides and text all seem to go together. That is very evident when we look at the Clinical Text from Drs. Rudy Bilous and Richard Donnelly, as they talk about


Editor's Note, Insulin Special Edition, August 2014

For years we have had methods for titrating patients with long-acting insulin and there have been very successful patient self-titration algorithms that have proven to work as well as physician-directed dosing. The problem has always been what to...


Letter from the Editor, #741:

Steve, Andrew and I are at the AADE Annual Meeting in Orlando. This meeting has a different flavor than some of the other meetings that we report on. While there are many clinical studies and new drug discoveries presented at the ADA and IDF...


Editor's Note, DCMS #200

For the past four years we have been providing you each week with a "Disaster Averted." These tidbits of experience submitted from your colleagues and from ISMP have pointed to the problems that can occur when we least expect it....


Letter from the Editor #740

Last week I started two patients on V-GO devices. For those of you who are not familiar with the...


Editor's Note, DCMS #199

Sometimes the simplest things can be the hardest to do correctly, and nowhere else could it be more devastating than when a glucagon kit is not used properly. In this week's Disaster Averted, see what could happen


Letter from the Editor, #739

Each year when I talk to educators about the AADE meeting, I often find out that they can't go because it is not their year. For most of them this means that their employer is only sending one or two educators a year and it is not their turn. If...


Editor's Note, DCMS #198

The mixing up of mixed insulins can cause problems for some of our patients especially if they are trying to achieve the best control possible. This week our Disaster Averted looks at


Editor's Note, Special GLP-1 Edition, July 2014

We know that patients lose a great deal of weight after bariatric surgery. Often times some of the weight comes off fast in the beginning and then slowly after that. More importantly these patients have a quick resolution of hyperglycemia and...


Letter from the Editor, #738: Afrezza

After a long battle and comments from many doubters the FDA has approved the inhaled insulin, Afrezza. As soon as the approval came the nay-sayers were quick to remind us of what a failure Exubera had been and there was no way that this new inhaled...


Editor's Note, DCMS #197

For the past year we have been providing you with a monthly white paper on SGLT-2 inhibitors and for the past 7 weeks we have...


Editor's Note, SGLT2-Inhibitor Special Edition, July 2014

When the first SGLT-2 inhibitor came to the market we went to doctors all over the country and asked them their opinions on this new class of drugs. The overwhelming response was "wait and see." Now a year later we asked them again to...


Letter from the Editor #737

There was an article in Diabetologia 2014 stating that, "Whey protein may represent a novel approach for...


Editor's Note, DCMS #196

First it was the Quintessential Quintet, then the Setaceous Sextet, and Septicidal Septet was next in our discussion of causes of hyperglycemia -- now, this week in our Homerun Slides, we look at


Letter from the Editor, #736: High Blood Sugar Mystery

Can you all help me with a couple of things? I know from experience that many of our readers are very physically active and health conscious. In talking with some of my colleagues, many select lower carb regimens...


Insulin Special Edition, July 2014

For many years insulin has been looked at as a treatment of last resort for patients with type 2 diabetes and so patients can be highly resistant to exogenous insulin when they start on injections and this resistance often grows as they continue to...


Editor's Note, DCMS #195:

This week, our special text is our Comprehensive List of Insulins. The most comprehensive and up-to-date list available,...


Letter from the Editor #735

It is interesting to listen to PCP's and other prescribers talk about their reluctance to use GLP-1 analogs in their practice. This class of drugs had a great presence at this year's ADA Scientific Sessions and many of the posters and presentations...


Special Edition, GLP-1 Summer 2014

When Steve and Andrew got back from the scientific sessions in San Francisco we put together an awesome overview of some of the new research and...


Editor's Note, DCMS #194

For most of us the explanation of why our patients get type 2 diabetes has been boiled down to its simplest form: we put too much glucose in our cells which makes us resistant to moving glucose into the cells so the pancreas tries to compensate by...


Letter from the Editor #734

I was working with my calculator earlier (my abacus is broken) and figured out that each of you who reads this week's newsletter saves about $2300. Our publisher, Stephen Freed, spent all of his time finding the best and most interesting articles...


Editor's Note, SGLT-2 Inhibitors June Special Edition

There was a lot of activity at the ADA this year and considerable attention was focused on the SGLT2 inhibitors. This class of drugs, which includes the currently approved canagliflozin and dapagliflozin and the hopefully-soon-to-be-approved...


Editor's Note, GLP-1 Special Edition June 2014

The last time the ADA was in San Francisco was 2008, and there were only a few of us who had even heard of a GLP-1. This novel hormone for the first time had a synthetic duplication that could be used to help control glucose levels. This time when...


Editor's Note DCMS #193: Is it sugar free or isn’t it?

Sometimes life is too sweet to be true and in this week's Disaster Averted, our patient finds out how sweet life can get if you grab the wrong bottle off...


Letter from the Editor #733

This week there is a lot of press on the use of insulin right after metformin and...


Editor's Note, DCMS #192

On my way to the airport Monday morning I was listening to a feature on NPR's Morning Edition about the use of pharmacists in the ER and of course my ears perked up. They were discussing how many drug errors occur in the hospital and how over 7,000...


Letter from the Editor, #732

For many years we have been talking about the value of almonds, walnuts, and pistachios in our patients health. We have published over 75 articles on the way to maximize these foods. This week we have a great feature on...


Editor's Note, DCMS #191

There are a plethora of new shows available to viewers today, and many of them are mysteries where a murder or crime occurs, dedicated law enforcement officials work to find out who committed the crime, and then go about punishing them. This...


Letter from the Editor, #731:

This week there is a great item about diabetes and cardiovascular problems, especially in women. In fact there are a total of four items that continue to expound on the relationship between diabetes, obesity and cardiovascular Disease. To make...


GLP-1 Analog Special Edition, May 2014

Way back in July 2011 we reviewed some of the emerging data showing that the GLP-1 RA class might have some value in improving cardiovascular outcomes. As newer entities in this class have been researched the cardiovascular studies required for...


Editor's Note, DCMS #190:

Can you remember where the phrase, "Warning, Will Robinson, warning warning!" came from? This week we have a real warning list for you to pay attention to as the information from ISMP in our Disaster Averted looks at


Letter from the Editor, Issue #730:

Last month I worked with Bruce Biundo, RPh, FACA, and Jerry D. Meece, RPh, FACA, FAADE, CDM, CDE, to develop a CE program on testosterone for pharmacists. This CE, The...


Editor's Note, SGLT2 Special Edition, May 2014

If you do a search on our website you will find over 150 articles and slide series about the SGLT-2 inhibitors. The content ranges from research studies to patient cases,...



Navigate through our listing of Letter From The Editor articles here.
Next Last

537 Total articles for Letter From The Editor


Browse our other news categories below.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Looking for a particular Newsletter Issue? Click Here


Cast Your Vote
When Afrezza is available, will you prescribe it immediately or wait until it has been on the market for a while?
CME/CE of the Week
Peter Blume, DPM

Category: Wound Care
Credits: .5


Advertisement


Search Articles On Diabetes In Control